---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-021105"
form_type: "8-K"
ticker: "NSPR"
cik: "0001433607"
company_name: "InspireMD, Inc."
filed_at: "2026-05-04T23:59:59+00:00"
generated_at: "2026-05-14T23:51:59.813706+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# InspireMD Q1 revenue $3.4M (+122% YoY); voluntary recall of CGuard Prime 135 cm

## Summary
- Net loss $13.7M ($0.16/share) vs $11.2M loss a year ago; operating expenses rose to $14.7M.
- GAAP gross profit $0.7M (20.2% margin); adjusted gross profit $1.2M (34.1%) excluding $0.5M impairment charge.
- Voluntary recall of CGuard Prime 135 cm; expected costs $700K returns + $650K inventory/remediation.
- FDA approved IDE for CGUARDIANS III trial of SwitchGuard NPS; CGuard Prime 80 cm TCAR approval expected H2 2026.
- Original CGuard FDA approval anticipated Q3 2026; over 625 cumulative procedures with CGuard Prime since launch.

## SEC filing metadata
- accession: 0001493152-26-021105
- form_type: 8-K
- ticker: NSPR
- cik: 0001433607
- company_name: InspireMD, Inc.
- filed_at: 2026-05-04T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1433607/000149315226021105/0001493152-26-021105-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1433607/000149315226021105/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-021105
- JSON: https://secwatch.observer/filing/0001493152-26-021105.json
- Plain text: https://secwatch.observer/filing/0001493152-26-021105.txt

## Key facts
- Earnings Releases
  InspireMD, Inc. reported first quarter ended March 31, 2026 results: revenue $3.4 million, net income $13.7 million, EPS $0.16 per basic and diluted share.
  - Period: first quarter ended March 31, 2026
  - Revenue: $3.4 million
  - Net income: $13.7 million
  - EPS: $0.16 per basic and diluted share
  - Result: reported results
  source text: expressly set forth by specific reference in such filing. --- EX-99.1 (EX-99.1) --- InspireMD Reports First Quarter 2026 Financial Results - Reports total Q1 2026 revenue of $3.4 million, representing year-over-year growth of 122% - - Received IDE approval from FDA to initiate the CGUARDIANS III clinical trial of its SwitchGuard neuro protection system for use in
  evidence_url: https://www.sec.gov/Archives/edgar/data/1433607/000149315226021105/0001493152-26-021105-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.